HOME >> BIOLOGY >> NEWS
Study Provides Guidance For Treating Patients With Brain Aneurysms

esota, and lead author of the study. "This study sheds significant light on the natural history of unruptured intracranial aneurysms, and offers physicians and their patients a new, low-risk option. Physicians and their patients will need to consider each situation individually."

The study enrolled 2,621 patients at 53 centers throughout the U.S., Canada, and Europe, and is the first large, multicenter study to use retrospective and prospective data to determine the natural course of UIAs in patients without a history of subarachnoid hemorrhage (group I) and patients with a history of subarachnoid hemorrhage (group II). Advances in imaging technology have made it possible to detect intracranial aneurysms before they rupture. Subjects in the NEJM study were diagnosed with UIAs through arteriography, an imaging technique that uses X-rays to photograph the arteries of the head made visible by a dye injected into the blood flowing through the artery. CT scans and MRI scans also can detect a brain aneurysm.

Dr. Wiebers and his colleagues found that for patients who have not had a previous subarachnoid hemorrhage, the risk of rupture for aneurysms smaller than 10 millimeters (mm) or about 1/3 of an inch in diameter was very low, less than 1/20 of 1 percent per year. For patients with a history of subarachnoid hemorrhage, the risk of rupture for the same sized aneurysm is about 11 times higher, about 1/2 of 1 percent per year. For aneurysms between 10 and 25 mm, the risk of rupture is still quite low, slightly less than 1 percent per year for both groups. The risk of rupture for giant aneurysms (greater than 25 mm in diameter) was about 6 percent for the first year for both groups. The exact position of the aneurysm in the brain was also a predictor of rupture in both groups.

Of course, the risk of rupture for an aneurysm must be compared to the overall risk of surgery to repair an aneurysm. For patients without a history of subarachnoid hemorrhage (
'"/>

Contact: Marcia Vital
301-496-5751
NIH/National Institute of Neurological Disorders and Stroke
9-Dec-1998


Page: 1 2 3

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
(Date:5/24/2013)... noise in one French Quarter neighborhood of New Orleans ... ordinances, Annette Hurley, PhD, Assistant Professor of Audiology at ... a third-year LSUHSC doctor of audiology student, recommend that ... health. Their case study is published online in the ... ., "An important part of an audiologist,s practice is ...
(Date:5/23/2013)... world,s most popular fruit, can be made both better-tasting ... varieties. , "Working with GM tomatoes that are ... a specific compound, allows us to pinpoint exactly how ... from the John Innes Centre. , The research could ... and shelf life characteristics because even higher levels of ...
(Date:5/23/2013)... suppresses lipid synthesis in the liver, UC Irvine endocrinologists ... liver diseases. , With this finding, Dr. Ellis ... in the field. Study results appear in the May ... , "The dogma in the steroid receptor field for ... the nucleus respond to steroid hormones by regulating genes ...
Breaking Biology News(10 mins):Please do try this at home 2The world's favorite fruit only better-tasting and longer-lasting 2UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
(Date:5/24/2013)... (PRWEB) May 24, 2013 Vestiage, ... lifestyle company focused on science-based research and development, ... anti-aging cosmeceuticals and nutraceuticals, announced today that it ... States for the sale of Reluma Skin Illuminating ... packet and application by sending an email to ...
(Date:5/23/2013)...  BioScrip, Inc. (NASDAQ: BIOS ) today ... 2013 Global Healthcare Conference to be held June 3-6, ... Richard Smith , President and Chief ... Chief Financial Officer, will present on Monday, June 3, ... About BioScrip BioScrip, Inc. provides comprehensive infusion ...
(Date:5/23/2013)... Ind. , May 23, 2013  Rahal Letterman ... in human cord blood stem cell banking and therapeutics, ... of the No. 16 Acorn Stairlifts Indy car driven ... for the remainder of the IZOD IndyCar 2013 season. ... (RLL) will work to support awareness of umbilical cord ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
Cached News: